Brief: Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27m-Mutant Diffuse Glioma Before Year-End
09/12/2024 21:02
Dec 10 (Reuters) - Chimerix Inc CMRX.O :
* CHIMERIX TO SUBMIT DORDAVIPRONE FOR ACCELERATED APPROVAL
TO U.S.
FDA FOR PATIENTS WITH RECURRENT H3 K27M-MUTANT DIFFUSE GLIOMA
BEFORE YEAR-END
* CHIMERIX INC - POTENTIAL APPROVAL FOR DORDAVIPRONE IN Q3
2025
Source text: urn:newsml:reuters.com:*:nGNX21Ybjd
Further company coverage: CMRX.O
((Reuters.Briefs@thomsonreuters.com;))